Poor Serologic Response to 2 Doses of an mRNA-based SARS-CoV-2 Vaccine in Lung Transplant Recipients

Transplantation. 2022 Jan 1;106(1):e103-e104. doi: 10.1097/TP.0000000000003966.

Authors

Thijs W Hoffman¹, B Meek², G T Rijkers³, D A van Kessel^{1

4}

Affiliations

¹ Department of Pulmonology, St. Antonius Hospital, Nieuwegein, Utrecht, The Netherlands.
² Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, Utrecht, The Netherlands.
³ Science Department, University College Roosevelt, Middelburg, The Netherlands.
⁴ Division of Heart and Lungs, Department of Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands.

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
Lung
RNA, Messenger / genetics
SARS-CoV-2
Transplant Recipients*

Substances

COVID-19 Vaccines
RNA, Messenger